WHWK · Whitehawk Therapeutics, Inc.
$4.46
-0.22 (-4.70%)
At close · Aug 14
Market Cap
$254.26M
Shares
57.01M
Whitehawk Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Whitehawk Therapeutics, Inc. (WHWK) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$15.00M
−$5.28M
'20 Q2
20-08-12
·
$231,000
−$2.89M
'20 Q3
20-11-10
·
$3.44M
−$18.27M
'22 Q2
22-08-10
·
$4.25M
−$14.47M
'22 Q3
22-11-09
▼62.3%
$5.23M
−$13.91M
'22 Q4
23-03-28
▲154.3%
$5.87M
−$15.22M
'23 Q1
23-05-10
▲80.4%
$6.20M
−$17.97M
'23 Q2
23-08-09
▲21%
$6.33M
−$16.27M
'23 Q4
24-03-13
▼8.8%
$5.35M
−$18.29M
'24 Q1
24-05-08
▼0.4%
$6.18M
−$14.58M
'24 Q2
24-08-07
LATEST
▲14.4%
$7.24M
−$18.27M
'24 Q4
25-03-18
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference Fireside Chat
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-03-18
Whitehawk Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Tumor target validation
Platform technology differentiation
ADC pipeline and portfolio
Revenue
$7.24M*
▲ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-07
Whitehawk Therapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone
PRECISION1 trial and TSC1/TSC2 interim data
FYARRO commercial performance in PEComa
Pipeline expansion: EEC and NET trials
Revenue
$6.18M
▼ 0.4% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Whitehawk Therapeutics, Inc. Q1 FY2024 Earnings Call
Positive tone
PRECISION1 trial enrollment and interim data
Endometrial (EEC) Phase II program
FYARRO commercial performance
Revenue
$5.35M
▼ 8.8% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Whitehawk Therapeutics, Inc. Q4 FY2023 Earnings Call
Revenue
$6.33M*
▲ 21% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q2
2023-08-09
Whitehawk Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$6.20M
▲ 80.4% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Whitehawk Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$5.87M
▲ 154.3% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Whitehawk Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$5.23M*
▼ 62.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Whitehawk Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$4.25M
Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Whitehawk Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$3.44M
Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-11-10
Whitehawk Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$231,000
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
Whitehawk Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$15.00M
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
Whitehawk Therapeutics, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–13 of 13 earnings calls
Key facts
CIK
1422142
CUSIP
00032Q104
13F (30d)
79 filings
78 filers
Visit website
Investor relations